ORTHO BIOTECH PROCRIT PRODUCT REPLACEMENT PROGRAM
ORTHO BIOTECH PROCRIT PRODUCT REPLACEMENT PROGRAM "replaces product free if it is used appropriately but the patient does not respond to treatment," Ortho Biotech President Dennis Longstreet told the Biotechnology Industry Organization annual meeting in Toronto May 25. Ortho has the program in place "in certain contractual arrangements," he said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth